S*Bio Out-licenses Myelofibrosis Treatment to Cell Therapeutics
S*BIO, the Singapore-based pharma that is developing targeted small molecule drugs for cancer, sold worldwide rights for its lead molecule to Cell Therapeutics of Seattle. Pacritinib is an oral JAK2 inhibitor that has completed Phase I and II trials for myelofibrosis. A global Phase III trial is scheduled to begin soon. To obtain control of pacritinib, Cell Therapeutics will pay S*Bio $15 million in cash and issue $15 million of preferred shares that are convertible into Cell Therapeutics common stock. More details.... Stock Symbol: (NSDQ: CTIC) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});  
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here